Although CGM‐based targets have been proposed for all people with diabetes,42 those specific to T2D have focused on people on intensive insulin therapy and evidence‐based CGM targets specifically for individuals with T2D on non‐intensive therapy are an unmet need. The gene discussed is INS; the disease is diabetes mellitus.